Combination targeted therapy in advanced renal cell carcinoma (Q37463883)

20 August 2017

1 reference

title

Combination targeted therapy in advanced renal cell carcinoma (English)

1 reference

20 August 2017

Jeffrey Sosman

1

1 reference

PubMed ID

19402058

20 August 2017

Igor Puzanov

series ordinal

2

1 reference

PubMed ID

19402058

20 August 2017

language of work or name

English

0 references

publication date

1 May 2009

1 reference

20 August 2017

1 reference

20 August 2017

115

1 reference

20 August 2017

10 Suppl

1 reference

20 August 2017

2368-2375

1 reference

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

20 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

Identification of the von Hippel-Lindau disease tumor suppressor gene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

Role of VHL gene mutation in human cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

The von Hippel-Lindau tumor suppressor protein and clear cell renal carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

Sorafenib in advanced clear-cell renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

Sunitinib in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

The von Hippel-Lindau tumor suppressor gene and kidney cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24234

7 January 2021

Identifiers

DOI

10.1002/CNCR.24234

1 reference

20 August 2017

1 reference

PubMed ID

19402058